Deep Braining...
TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc.
XNAS:ACRS
2.86
-0.69%

Ask
$2.90 - 100.00
Bid
$2.74 - 40.00
Low
$2.76
High
$2.92
Open
$2.9
Prev Close
$2.88
52W High
4.24
52W Low
1.05
Volume
502608
Avg Vol (3m)
1148849.6
Float
92507561.28
Chart
TendieTensor AI Analysis

Company
Asset Type: Common Stock
SIC Code: 2834
Sector: Health Technology
Industry: Pharmaceuticals: Major
Date Listed: 10/07/2015
Primary Exchange: XNAS

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Phone: 484-324-7933
Address: 701 Lee Road
Address 2: Suite 103
City: Wayne
State: PA
Postal Code: 19087
TendieTensor AI Analyst Recommendation:
Fundamentals
Total Employees:
64
P/E (TTM)
-2.050000
P/B (TTM)
2.552950
EPS
-0.12
Round Lot
100
Composit FIGI
BBG003LF0QR9
Share Class FIGI
BBG003LF0QS8
Share Class Shares Outstanding
108.33M
Weighted Shares Outstanding
108.34M

Technicals
RSI (14)
MACD Line
MACD Signal
SMA 20
SMA 50
EMA 50
Trend
Short Interest
Days to Cover
Higher = harder to cover
Short Interest Δ
Prev: —
Short Volume Ratio (Today)
5D avg:
Squeeze Score (0–100)
Discussion
Login to participate in discussions.
Recent News
Related Stocks

Based on the portfolios of people who own ACRS. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.